Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)

NCT01438710 | Completed Phase 3 Results

• 1 other identifier: LCP-Tacro 3003
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 10

Brief Summary

This study will evaluate and measure symptomatic hand tremor in stable kidney transplant subjects on Prograf or generic tacrolimus maintenance therapy at baseline (pre-conversion) and following conversion to LCP-Tacro. This study will also evaluate the safety of LCP-Tacro compared with Prograf or generic tacrolimus

Conditions

Renal Failure; Tremors

Outcome Measures

Primary Outcomes (1)

• Evaluation of Hand Tremor and Stable Kidney Transplant Patients When Switched From Prograf to LCP-Tacro.

  The primary efficacy endpoint is the mean change from baseline (ie Day 7) in the Fahn-Tolosa-Marin Clinical Rating Scale (FTM) for overall tremor score 7 days after (ie, Day 14) LCP-Tacro conversion. The overall FTM score was 0 to 100 where higher scores denoted worst/more severe tremor. Below the mean total score and standard deviation for each treatment is given in addition to the mean change.

  14 days

Study Arms (2)

LCP-Tacro

EXPERIMENTAL

LCP Tacro tables for once daily oral administration

Drug: LCP-Tacro

Prograf

EXPERIMENTAL

Tacrolimus capsules for twice daily oral administration

Drug: Prograf

Interventions

Prograf DRUG

Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.

Also known as: tacrolimus

Prograf

LCP-Tacro DRUG

LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.

Also known as: tacrolimus

LCP-Tacro

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must be able to give written consent
• Men and women between 18 and 65 years of age who are recipients of a kidney transplant between 1 month and 5 years prior to the screening date
• Subjects with at least one complaint of tremor and existence of postural tremor or action tremor on finger to nose as demonstrated by a score of at least 2 of any of the 4 upper extremity (UE) postural or action and intention assessments on the FTM clinical rating scale
• Subjects experiencing symptomatic drug-induced hand tremor associated with use of Prograf or generic tacrolimus as demonstrated by responding "no" to each of the following question: "Did you have a tremor that you noticed prior to starting Prograf or generic tacrolimus for your kidney transplant?", or "Are you aware of a tremor that runs in your family?"
• Subjects taking a stable dose of oral Prograf or generic tacrolimus capsules for at least 7 days with trough levels of tacrolimus between 3 to 12 ng/mL. Subjects must maintain tacrolimus trough levels in this range during the 7 day Prograf or generic tacrolimus treatment phase (note that 1 dose adjustment at Study Day 3 \[a.m.dose\] is allowed for those subjects whose Day0/1 trough level is out of range.
• Women of childbearing potential must have a negative serum pregnancy test within 7 days before study start.

You may not qualify if:

• Recipients of any transplants including organ other than kidney and bone marrow
• Subjects with an estimated glomerular filtration rate (eGFR) (MDRD7) \<30mL/min at Screening
• Subjects incapable of understanding the purposed and risks of the study, who cannot give written informed consent and who are unwilling or unable to comply with study protocol requirements
• Pregnant or nursing women
• Subjects with reproductive potential who are unwilling/unable to use a double barrier method of contraception
• Subjects who were treated with any other investigational agent within 3 months prior to screening
• Subjects who are taking drugs that are likely to affect the PK levels of tacrolimus and are not on a stable dose of those medications (see Appendix 1)
• Subjects who have essential tremor, Parkinsonism, or tremor from any cause other than tacrolimus-induced tremor;
• Subjects who are taking or had been taking any drug within the past 30 days that is well known to promote tremors, including: amiodarone, beta-agonist inhalers (such as albuterol), cyclosporine, lithium, metoclopramide, theophylline, or valproate,or taking within the past 6 months the dopamine blocking agents (antipsychotics) (note, other such medication may be considered on a case-by-case basis at the discretion of the investigator);
• Subjects who taking drugs that reduce tremor, and are not on stable doses of the treatment (ie, had not been taking the medication for a minimum of 30 days), including: gabapentin (note, other such medications may be considered on a case-by-case basis at the discretion of the investigator);
• Subjects on concurrent immunosuppression with MMD (CellCept) of MPS delayed-release tables (Myfortic), or generic versions of these medication, who have not been on stable doses at least 7 days prior to screening
• Subjects receiving prednisone or equivalent at a dose \>10 mg per day
• Either subjects with an episode of acute rejection requiring treatment or subjects with an episode of biopsy-proven or suspected acute rejections that requires treatment within 3 months of screening
• Subjects who are being actively treated for cancer (with the exception of non-invasive basal cell or squamous cell) or human immunodeficiency virus (HIV)
• Subjects with any form of current drug or alcohol abuse

Sponsors & Collaborators

• Veloxis Pharmaceuticals: lead

Study Sites (10)

Clinical Investigative Site 006

Los Angeles, California, 90057, United States

Location

Clinical Investigative Site 1049

San Diego, California, 92123, United States

Location

Clinical Investigative Site 007

Aurora, Colorado, 80045, United States

Location

Clinical Investigative Site 005

New Haven, Connecticut, 06520, United States

Location

Clinical Investigative Site 004

Lexington, Kentucky, 40536, United States

Location

Clinical Investigative Site 008

Minneapolis, Minnesota, 55455, United States

Location

Clinical Investigative Site 003

St Louis, Missouri, 63110, United States

Location

Clinical Investigative Site 002

Oklahoma City, Oklahoma, 73112, United States

Location

Clinical Investigative Site 009

Nashiville, Tennessee, 37232, United States

Location

Clinical Investigative Site 012

Dallas, Texas, 75246, United States

Location

MeSH Terms

Conditions

Renal Insufficiency; Tremor

Interventions

Tacrolimus

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Dyskinesias; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Macrolides; Lactones; Organic Chemicals

Results Point of Contact

• Title: Christina Sylvest
• Organization: Veloxis Pharmaceuticals

csy@veloxis.com

+4520553877

Study Officials

• Alan Glicklich, MD

  VP, Clinical Development

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 20, 2011
• First Posted: September 22, 2011
• Study Start: December 1, 2011
• Primary Completion: August 1, 2012
• Study Completion: July 1, 2015
• Last Updated: October 1, 2015
• Results First Posted: May 8, 2015

Record last verified: 2015-09

Locations

US (10)